Intellia Therapeutics Files Routine 8-K on Jan 31 Event
Ticker: NTLA · Form: 8-K · Filed: Feb 1, 2024 · CIK: 1652130
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, compliance, 8-K
TL;DR
**NTLA filed a standard 8-K, signaling routine compliance and no major news.**
AI Summary
Intellia Therapeutics, Inc. filed an 8-K on February 1, 2024, reporting an event that occurred on January 31, 2024. This filing is a routine disclosure, specifically a Regulation FD Disclosure and Financial Statements and Exhibits, indicating that the company is maintaining compliance with SEC reporting requirements. For investors, this filing primarily signals ongoing operational transparency and adherence to regulatory obligations, which is a foundational aspect of corporate governance and investor confidence.
Why It Matters
This filing demonstrates Intellia Therapeutics' commitment to regulatory compliance and transparency, which is crucial for maintaining investor trust and a stable market perception.
Risk Assessment
Risk Level: low — This 8-K is a routine filing for Regulation FD Disclosure and exhibits, indicating no immediate new risks or significant changes to the company's operations.
Analyst Insight
A smart investor would note this as a routine compliance filing, indicating no immediate new information requiring a change in investment strategy. It reinforces the company's adherence to regulatory standards.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 31, 2024 (date) — date of the earliest event reported
- February 1, 2024 (date) — date the 8-K was filed
- 001-37766 (other) — Commission File Number for Intellia Therapeutics, Inc.
- NTLA (other) — trading symbol for Intellia Therapeutics, Inc. Common Stock
FAQ
What is the purpose of this 8-K filing by Intellia Therapeutics, Inc.?
This 8-K filing serves as a 'Current Report' pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically for 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' as per the 'ITEM INFORMATION' section.
When was the earliest event reported in this 8-K filing?
The 'Date of Report (Date of earliest event reported)' is stated as January 31, 2024.
What is the trading symbol and exchange for Intellia Therapeutics, Inc.'s common stock?
The 'Trading Symbol(s)' for their Common Stock, par value $0.0001 per share, is NTLA, and it is registered on 'The Nasdaq Global Market'.
Where is Intellia Therapeutics, Inc.'s principal executive office located?
The 'Address of Principal Executive Offices' is 40 Erie Street, Suite 130, Cambridge, Massachusetts, 02139.
What is Intellia Therapeutics, Inc.'s state of incorporation?
Intellia Therapeutics, Inc. is incorporated in 'Delaware', as indicated under 'State or Other Jurisdiction of Incorporation'.
Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-02-01 16:05:12
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share NTLA The Nasdaq Global Ma
Filing Documents
- ntla-20240131.htm (8-K) — 42KB
- ntla-ex99_1.htm (EX-99.1) — 28KB
- img149557450_0.jpg (GRAPHIC) — 12KB
- 0000950170-24-009776.txt ( ) — 204KB
- ntla-20240131.xsd (EX-101.SCH) — 24KB
- ntla-20240131_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 31, 2024, the Company issued a press release titled "Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine." A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference . The information under this Item 7.01, including Exhibit 99.1 hereto, are being furnished herewith and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated January 31, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Intellia Therapeutics, Inc. Date: February 1, 2024 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President